A Study to Develop and Validate a New Disease-Specific Quality of Life Index for Sporadic Vestibular Schwannoma

Overview

About this study

The purpose of this study is to develop and validate a new disease-specific, quality-of-life (QOL) index for sporadic Vestibular Schwannoma (VS) that addresses key shortcomings of previous instruments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Able to read and write English fluently.
Can sign consent for themselves.
Age 18 years or older.
Diagnosis of sporadic Vestibular Schwannoma (VS) (also called acoustic neuroma).

Exclusion Criteria:

Age less than 18 years old.
Diagnosis of VS secondary to neurofibromatosis type 2 (NF2).
Lack of capacity to consent.
Unable to read/write English fluently.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Kathleen Yost, Ph.D.	Closed-enrolling by invitation What is this? (?) "Close" Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.	Contact information: Nicole Tombers R.N. (507) 293-2445 Tombers.Nicole@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kathleen Yost, Ph.D.

Closed-enrolling by invitation

Contact information:

Nicole Tombers R.N.

(507) 293-2445

Tombers.Nicole@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials